{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T21:49:24Z","timestamp":1776289764668,"version":"3.50.1"},"reference-count":238,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.cyto.2025.157025","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:51:30Z","timestamp":1757771490000},"page":"157025","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Delving deeper in the eye of the hurricane: Immunopathogenesis &amp; molecular characterization of cytokine storm in COVID-19, association with disease severity &amp; the therapeutic regimens"],"prefix":"10.1016","volume":"195","author":[{"given":"Umaiya","family":"Muzaffar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamal Shaik","family":"Fakiruddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasaman","family":"Talebiashtiany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syahril","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2025.157025_bb0005","series-title":"Pathology and Pathogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","author":"Afewerky","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0010","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.7423","article-title":"Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2): an update","author":"Pal","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.cyto.2025.157025_bb0015","series-title":"Interaction of SARS-CoV-2 and Other Coronavirus with ACE (Angiotensin-Converting Enzyme)-2 as their Main Receptor: Therapeutic Implications","author":"Davidson","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0020","series-title":"The COVID-19 Cytokine Storm; What We Know So Far","author":"Ragab","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0025","series-title":"Immunology of SARS-CoV-2 Infection","author":"Gabdoulkhakova","year":"2024"},{"key":"10.1016\/j.cyto.2025.157025_bb0030","series-title":"How COVID-19 Induces Cytokine Storm with High Mortality","author":"Hojyo","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0035","series-title":"Respiratory Epithelial Cell Responses to SARS-CoV-2 in COVID-19","author":"Bridges","year":"2022"},{"issue":"11","key":"10.1016\/j.cyto.2025.157025_bb0040","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/infdis\/jiaa150","article-title":"Characteristics of peripheral lymphocyte subset alteration in covid-19 pneumonia","volume":"221","author":"Wang","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cyto.2025.157025_bb0045","series-title":"Comparison of COVID-19 Induced Respiratory Failure and Typical ARDS: Similarities and Differences","author":"Lu","year":"2022"},{"key":"10.1016\/j.cyto.2025.157025_bb0050","series-title":"Tackling the Cytokine Storm in COVID-19, Challenges and Hopes","author":"Abdin","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0055","article-title":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial","volume":"369","author":"Tang","year":"2020","journal-title":"The BMJ"},{"issue":"5","key":"10.1016\/j.cyto.2025.157025_bb0060","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.4103\/jfmpc.jfmpc_728_20","article-title":"Preventive and treatment strategies of COVID-19: from community to clinical trials","volume":"9","author":"Sahu","year":"2020","journal-title":"J. Family Med. Prim. Care"},{"key":"10.1016\/j.cyto.2025.157025_bb0065","series-title":"The Role of Dysregulated Immune Responses in COVID-19 Pathogenesis","author":"Tahaghoghi-Hajghorbani","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0070","series-title":"Role of Monocytes\/Macrophages in COVID-19 Pathogenesis: Implications for Therapy","author":"G\u00f3mez-Rial","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0075","series-title":"SARS-CoV-2 and innate Immunity: The Good, The Bad, and The \u201cgoldilocks\u201d","author":"Sievers","year":"2024"},{"key":"10.1016\/j.cyto.2025.157025_bb0080","series-title":"T-cell Responses and Therapies Against SARS-CoV-2 Infection","author":"Toor","year":"2021"},{"issue":"1","key":"10.1016\/j.cyto.2025.157025_bb0085","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaci.2020.04.009","article-title":"Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2","volume":"146","author":"Jackson","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2025.157025_bb0090","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00251-023-01326-4","article-title":"The COVID-19 inflammation and high mortality mechanism trigger","volume":"76","author":"Str\u00f3\u017c","year":"2024","journal-title":"Immunogenetics"},{"key":"10.1016\/j.cyto.2025.157025_bb0095","series-title":"Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration","author":"Chen","year":"2021"},{"key":"10.1016\/j.cyto.2025.157025_bb0100","series-title":"New understanding of the damage of SARS-CoV-2 infection outside the respiratory system","author":"Zhang","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0105","series-title":"Renin\u2013angiotensin system inhibitors positively impact on multiple aging regulatory pathways: Could they be used to protect against human aging?","author":"de Cavanagh","year":"2024"},{"key":"10.1016\/j.cyto.2025.157025_bb0110","series-title":"Roles of the ACE\/Ang II\/AT1R Pathway, Cytokine Release, and Alteration of Tight Junctions in COVID-19 Pathogenesis","author":"Ashour","year":"2023"},{"key":"10.1016\/j.cyto.2025.157025_bb0115","series-title":"Angiotensin II receptors: impact for COVID-19 severity","author":"Aksoy","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0120","series-title":"Inflammatory cell death: how macrophages sense neighbouring cell infection and damage","author":"Wang","year":"2023"},{"key":"10.1016\/j.cyto.2025.157025_bb0125","series-title":"Roles of prr-mediated signaling pathways in the regulation of oxidative stress and inflammatory diseases","author":"Li","year":"2021"},{"key":"10.1016\/j.cyto.2025.157025_bb0130","series-title":"Studying the Immunomodulatory Effects of SARS-CoV-2 Viral Proteins in Human Lung Epithelial Cell Lines","author":"D\u00fcrkoop","year":"2021"},{"issue":"8","key":"10.1016\/j.cyto.2025.157025_bb0135","article-title":"SARS-CoV-2 n protein targets TRIM25-mediated RIG-I activation to suppress innate immunity","volume":"13","author":"Savellini","year":"2021","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.cyto.2025.157025_bb0140","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1080\/22221751.2020.1780953","article-title":"SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists","volume":"9","author":"Yuen","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.cyto.2025.157025_bb0145","series-title":"Covid-19: perspectives on innate immune evasion","author":"Taefehshokr","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0150","series-title":"Type i interferons in covid-19 pathogenesis","author":"Palermo","year":"2021"},{"issue":"1","key":"10.1016\/j.cyto.2025.157025_bb0155","doi-asserted-by":"crossref","DOI":"10.1186\/s13578-022-00770-1","article-title":"SARS-CoV-2 NSP13 helicase suppresses interferon signaling by perturbing JAK1 phosphorylation of STAT1","volume":"12","author":"Fung","year":"2022","journal-title":"Cell Biosci."},{"issue":"2","key":"10.1016\/j.cyto.2025.157025_bb0160","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciab376","article-title":"Differential cytokine signatures of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza infection highlight key differences in pathobiology","volume":"74","author":"Karaba","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cyto.2025.157025_bb0165","series-title":"The role of the nuclear factor-kappa B (NF-\u03baB) pathway in SARS-CoV-2 infection","author":"Kesika","year":"2024"},{"key":"10.1016\/j.cyto.2025.157025_bb0170","series-title":"Virology, epidemiology, pathogenesis, and control of covid-19","author":"Jin","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0175","series-title":"Innate Immunity in Protection and Pathogenesis during Coronavirus Infections and COVID-19","author":"Subbarao Malireddi","year":"2025"},{"key":"10.1016\/j.cyto.2025.157025_bb0180","series-title":"The immune response to SARS-CoV-2 and COVID-19 immunopathology \u2013 current perspectives","author":"Boechat","year":"2021"},{"key":"10.1016\/j.cyto.2025.157025_bb0185","series-title":"COVID-19 and the role of cytokines in this disease","author":"Hasanvand","year":"2022"},{"issue":"1","key":"10.1016\/j.cyto.2025.157025_bb0190","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/22221751.2020.1770129","article-title":"Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors","volume":"9","author":"Han","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.cyto.2025.157025_bb0195","series-title":"Pathophysiological mechanisms of ARDS: a narrative review from molecular to organ-level perspectives","author":"Zhou","year":"2025"},{"key":"10.1016\/j.cyto.2025.157025_bb0200","series-title":"Cytokine storm induced by SARS-CoV-2","author":"Song","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0205","series-title":"The signal pathways and treatment of cytokine storm in COVID-19","author":"Yang","year":"2021"},{"key":"10.1016\/j.cyto.2025.157025_bb0210","series-title":"Traumatic inflammatory response: pathophysiological role and clinical value of cytokines","author":"Li","year":"2024"},{"key":"10.1016\/j.cyto.2025.157025_bb0215","series-title":"A Highlight on Prevention and Protection: Cytokine Storm and Covid-19, a Chronicle of Pro-Inflammatory Cytokines","author":"Mondal","year":"2024"},{"issue":"13","key":"10.1016\/j.cyto.2025.157025_bb0220","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148517","article-title":"Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19","volume":"131","author":"Ahn","year":"2021","journal-title":"J. Clin. Investig."},{"issue":"6","key":"10.1016\/j.cyto.2025.157025_bb0225","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/covid5060085","article-title":"SARS-CoV-2 replication revisited: molecular insights and current and emerging antiviral strategies","volume":"5","author":"Subong","year":"2025","journal-title":"COVID"},{"key":"10.1016\/j.cyto.2025.157025_bb0230","series-title":"Sars-cov-2 subgenomic rnas: characterization, utility, and perspectives","author":"Long","year":"2021"},{"key":"10.1016\/j.cyto.2025.157025_bb0235","series-title":"Dynamics of innate immunity in SARS-CoV-2 infections: exploring the impact of natural killer cells, inflammatory responses, viral evasion strategies, and severity","author":"Batista","year":"2025"},{"key":"10.1016\/j.cyto.2025.157025_bb0240","series-title":"Unraveling the complexities of toll-like receptors: from molecular mechanisms to clinical applications","author":"Chen","year":"2024"},{"key":"10.1016\/j.cyto.2025.157025_bb0245","series-title":"Pattern-Recognition Receptors (PRRs) in SARS-CoV-2","author":"Isazadeh","year":"2023"},{"key":"10.1016\/j.cyto.2025.157025_bb0250","series-title":"MDA5 is a major determinant of developing symptoms in critically ill COVID-19 patients","author":"Maiti","year":"2024"},{"issue":"3","key":"10.1016\/j.cyto.2025.157025_bb0255","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2024.13163","article-title":"Essential contribution of the JAK\/STAT pathway to carcinogenesis, lytic infection of herpesviruses and pathogenesis of COVID-19 (review)","volume":"29","author":"Li","year":"2024","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.cyto.2025.157025_bb0260","series-title":"Interferon-I modulation and natural products: unraveling mechanisms and therapeutic potential in severe COVID-19","author":"Song","year":"2024"},{"key":"10.1016\/j.cyto.2025.157025_bb0265","series-title":"Immune responses in COVID-19 patients: insights into cytokine storms and adaptive immunity kinetics","author":"Zhang","year":"2024"},{"key":"10.1016\/j.cyto.2025.157025_bb0270","series-title":"Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines: cytokine storm: the elements of rage!","author":"Fara","year":"2020"},{"issue":"3","key":"10.1016\/j.cyto.2025.157025_bb0275","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00299-20","article-title":"Critical determinants of cytokine storm and type i interferon response in COVID-19 pathogenesis","volume":"34","author":"Ramasamy","year":"2021","journal-title":"Clin. Microbiol. Rev."},{"issue":"5","key":"10.1016\/j.cyto.2025.157025_bb0280","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","article-title":"SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues","volume":"181","author":"Ziegler","year":"2020","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.cyto.2025.157025_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009878","article-title":"Differential plasmacytoid dendritic cell phenotype and type i interferon response in asymptomatic and severe COVID-19 infection","volume":"17","author":"Severa","year":"2021","journal-title":"PLoS Pathog."},{"issue":"5","key":"10.1016\/j.cyto.2025.157025_bb0290","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced host response to SARS-CoV-2 drives development of COVID-19","volume":"181","author":"Blanco-Melo","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cyto.2025.157025_bb0295","series-title":"Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: role of lncRNAs in cytokine storm modulation","author":"Paniri","year":"2020"},{"issue":"10223","key":"10.1016\/j.cyto.2025.157025_bb0300","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cyto.2025.157025_bb0305","author":"Tang"},{"key":"10.1016\/j.cyto.2025.157025_bb0310","article-title":"The characterization of disease severity associated IgG subclasses response in COVID-19 patients","volume":"12","author":"Luo","year":"2021","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.cyto.2025.157025_bb0315","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10092017","article-title":"HGF, IL-1\u03b1, and IL-27 are robust biomarkers in early severity stratification of COVID-19 patients","volume":"10","author":"Tamayo-Velasco","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.cyto.2025.157025_bb0320","article-title":"Extensive study on hematological, immunological, inflammatory markers, and biochemical profile to identify the risk factors in COVID-19 patients","volume":"2022","author":"Ali","year":"2022","journal-title":"Int. J. Inflam."},{"issue":"9","key":"10.1016\/j.cyto.2025.157025_bb0325","doi-asserted-by":"crossref","first-page":"e632","DOI":"10.1016\/S2589-7500(22)00112-1","article-title":"Development of a multiomics model for identification of predictive biomarkers for COVID-19 severity: a retrospective cohort study","volume":"4","author":"Byeon","year":"2022","journal-title":"Lancet Digit. Health"},{"key":"10.1016\/j.cyto.2025.157025_bb0330","series-title":"COVID-19: Integrating the Complexity of Systemic and Pulmonary Immunopathology to Identify Biomarkers for Different Outcomes","author":"Fraga-Silva","year":"2021"},{"issue":"1","key":"10.1016\/j.cyto.2025.157025_bb0335","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-98505-y","article-title":"Cytokine profiles dynamics in COVID-19 patients: a longitudinal analysis of disease severity and outcomes","volume":"15","author":"Ghaffarpour","year":"2025","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.cyto.2025.157025_bb0340","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-68509-x","article-title":"CT features of COVID-19 patients with two consecutive negative RT-PCR tests after treatment","volume":"10","author":"Fu","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.cyto.2025.157025_bb0345","doi-asserted-by":"crossref","DOI":"10.1186\/s12985-021-01588-y","article-title":"Specific cytokines in the inflammatory cytokine storm of patients with COVID-19-associated acute respiratory distress syndrome and extrapulmonary multiple-organ dysfunction","volume":"18","author":"Wang","year":"2021","journal-title":"Virol. J."},{"key":"10.1016\/j.cyto.2025.157025_bb0350","series-title":"Crosstalk between platelets and SARS-CoV-2: implications in Thrombo-inflammatory complications in COVID-19","author":"Zhao","year":"2023"},{"key":"10.1016\/j.cyto.2025.157025_bb0355","series-title":"Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes","author":"Leisman","year":"2020"},{"issue":"7","key":"10.1016\/j.cyto.2025.157025_bb0360","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24881","article-title":"IL-6 at the center of cytokine storm: circulating inflammation mediators as biomarkers in hospitalized COVID-19 patients","volume":"37","author":"Elbadawy","year":"2023","journal-title":"J. Clin. Lab. Anal."},{"issue":"1","key":"10.1016\/j.cyto.2025.157025_bb0365","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26888-3","article-title":"COVID-19 genetic risk variants are associated with expression of multiple genes in diverse immune cell types","volume":"12","author":"Schmiedel","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cyto.2025.157025_bb0370","series-title":"The role of macrophages in the pathogenesis of SARS-CoV-2-associated acute respiratory distress syndrome","author":"Kosyreva","year":"2021"},{"key":"10.1016\/j.cyto.2025.157025_bb0375","series-title":"SARS-CoV-2-associated lymphopenia: possible mechanisms and the role of CD147","author":"Shouman","year":"2024"},{"key":"10.1016\/j.cyto.2025.157025_bb0380","doi-asserted-by":"crossref","unstructured":"Z. Feng et al., \u2018The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes Running title: SARS-CoV-2 infects human spleens and lymph nodes\u2019, doi: https:\/\/doi.org\/10.1101\/2020.03.27.20045427.","DOI":"10.1101\/2020.03.27.20045427"},{"issue":"4","key":"10.1016\/j.cyto.2025.157025_bb0385","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0301330","article-title":"Infection kinetics, syncytia formation, and inflammatory biomarkers as predictive indicators for the pathogenicity of SARS-CoV-2 Variants of Concern in Calu-3 cells","volume":"19","author":"Purwono","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.cyto.2025.157025_bb0390","series-title":"PANoptosis: A Cell Death Characterized by Pyroptosis, Apoptosis, and Necroptosis","author":"Shi","year":"2023"},{"key":"10.1016\/j.cyto.2025.157025_bb0395","series-title":"Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2","author":"Catanzaro","year":"2020"},{"issue":"1","key":"10.1016\/j.cyto.2025.157025_bb0400","article-title":"ACE2-independent infection of T lymphocytes by SARS-CoV-2","volume":"7","author":"Shen","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.cyto.2025.157025_bb0405","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jaci.2020.04.027","article-title":"Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19","volume":"146","author":"Yang","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.cyto.2025.157025_bb0410","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)","volume":"11","author":"Diao","year":"2020","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2025.157025_bb0415","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/infdis\/jiaa363","article-title":"Serum cytokine and chemokine profile in relation to the severity of coronavirus disease 2019 in China","volume":"222","author":"Chi","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cyto.2025.157025_bb0420","series-title":"COVID-19: immunopathology and its implications for therapy","author":"Cao","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0425","series-title":"Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study","author":"Tan","year":"2020"},{"issue":"1","key":"10.1016\/j.cyto.2025.157025_bb0430","article-title":"The potential for antibody-dependent enhancement of SARS-CoV-2 infection: translational implications for vaccine development","volume":"5","author":"Wang","year":"2021","journal-title":"J. Clin. Transl. Sci."},{"key":"10.1016\/j.cyto.2025.157025_bb0435","series-title":"Fc-Fc\u03b3R interactions during infections: From neutralizing antibodies to antibody-dependent enhancement","author":"Edgar","year":"2024"},{"key":"10.1016\/j.cyto.2025.157025_bb0440","series-title":"Cytokine storm intervention in the early stages of COVID-19 pneumonia","author":"Sun","year":"2020"},{"issue":"5","key":"10.1016\/j.cyto.2025.157025_bb0445","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01987-21","article-title":"Antibody-dependent enhancement of SARS-CoV-2 infection is mediated by the IgG receptors FcgRIIA and FcgRIIIA but does not contribute to aberrant cytokine production by macrophages","volume":"12","author":"Maemura","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.cyto.2025.157025_bb0450","series-title":"Antibody-Dependent Enhancement of Coronaviruses","author":"Tao","year":"2025"},{"key":"10.1016\/j.cyto.2025.157025_bb0455","series-title":"Immunopathogenesis and Treatment of Cytokine Storm in COVID-19","author":"Kim","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0460","series-title":"JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy","author":"Satarker","year":"2021"},{"key":"10.1016\/j.cyto.2025.157025_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106765","article-title":"Design, synthesis, and pharmacological evaluation of quinazoline derivatives as novel and potent pan-JAK inhibitors","volume":"140","author":"Xiang","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.cyto.2025.157025_bb0470","series-title":"Systematic Review: JAK-STAT Regulation and Its Impact on Inflammation Response in ARDS from COVID-19","author":"Rodriguez","year":"2024"},{"key":"10.1016\/j.cyto.2025.157025_bb0475","author":"Sacchi"},{"key":"10.1016\/j.cyto.2025.157025_bb0480","series-title":"Mechanisms of Impairment of Interferon Production by SARS-CoV-2","author":"Hoang","year":"2023"},{"issue":"10","key":"10.1016\/j.cyto.2025.157025_bb0485","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1002\/jmv.25987","article-title":"In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs","volume":"92","author":"Choudhury","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.cyto.2025.157025_bb0490","series-title":"Revisiting Pleiotropic Effects of Type I Interferons: Rationale for Its Prophylactic and Therapeutic Use Against SARS-CoV-2","author":"Garcia-del-Barco","year":"2021"},{"key":"10.1016\/j.cyto.2025.157025_bb0495","series-title":"Contribution to Pathogenesis of Accessory Proteins of Deadly Human Coronaviruses","author":"Hurtado-Tamayo","year":"2023"},{"key":"10.1016\/j.cyto.2025.157025_bb0500","series-title":"The Triumvirate of NF-\u03baB, Inflammation and Cytokine Storm in COVID-19","author":"Attiq","year":"2021"},{"issue":"6","key":"10.1016\/j.cyto.2025.157025_bb0505","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.immuni.2020.04.023","article-title":"Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals","volume":"52","author":"Ni","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.cyto.2025.157025_bb0510","series-title":"Pleiotropy and specificity: insights from the interleukin 6 family of cytokines","author":"Murakami","year":"2019"},{"issue":"7821","key":"10.1016\/j.cyto.2025.157025_bb0515","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.cyto.2025.157025_bb0520","doi-asserted-by":"crossref","DOI":"10.3390\/v13040645","article-title":"The spike glycoprotein of sars-cov-2 binds to \u03b21 integrins expressed on the surface of lung epithelial cells","volume":"13","author":"Park","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.cyto.2025.157025_bb0525","series-title":"Electrochemical Immunosensors for the Detection of Cytokine Tumor Necrosis Factor Alpha: A Review","author":"Filik","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0530","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1473-3099(20)30270-X","article-title":"Baricitinib for COVID-19: a suitable treatment? \u201c authors\u201d reply","volume":"20","author":"Richardson","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.cyto.2025.157025_bb0535","series-title":"\u2018COVID-19: Immunopathology, Pathophysiological Mechanisms, and Treatment Options","author":"van Eijk","year":"2021"},{"issue":"8","key":"10.1016\/j.cyto.2025.157025_bb0540","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/s41587-020-0602-4","article-title":"COVID-19 severity correlates with airway epithelium\u2013immune cell interactions identified by single-cell analysis","volume":"38","author":"Chua","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.cyto.2025.157025_bb0545","doi-asserted-by":"crossref","first-page":"8394","DOI":"10.1038\/s41467-024-52803-7","article-title":"A basally active cGAS-STING pathway limits SARS-CoV-2 replication in a subset of ACE2 positive airway cell models","volume":"15","author":"Puray-Chavez","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.cyto.2025.157025_bb0550","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00018-024-05520-9","article-title":"Altered ACE2 and interferon landscape in the COVID-19 microenvironment correlate with the anti-PD-1 response in solid tumors","volume":"81","author":"Subbarayan","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"issue":"6","key":"10.1016\/j.cyto.2025.157025_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106314","article-title":"Inflammatory cytokine responses in pediatric tuberculosis with or without SARS-CoV-2 seropositivity","volume":"89","author":"Kumar","year":"2024","journal-title":"J. Infect."},{"issue":"12","key":"10.1016\/j.cyto.2025.157025_bb0560","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s41588-020-00731-9","article-title":"Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor","volume":"52","author":"Onabajo","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cyto.2025.157025_bb0565","series-title":"Interferon-regulated genetic programs and JAK\/STAT pathway activate the intronic promoter of the short ACE2 isoform in renal proximal tubules","author":"Jankowski","year":"2021"},{"key":"10.1016\/j.cyto.2025.157025_bb0570","series-title":"SARS-CoV-2 infection: the role of cytokines in COVID-19 disease","author":"Costela-Ruiz","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0575","series-title":"\u2018Pathological Inflammation in Patients with COVID-19: A Key Role for Monocytes and Macrophages","author":"Merad","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0580","series-title":"The Trinity of COVID-19: Immunity, Inflammation and Intervention","author":"Tay","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0585","series-title":"Epidemiology of covid-19","author":"Bulut","year":"2020"},{"issue":"23","key":"10.1016\/j.cyto.2025.157025_bb0590","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine Storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2025.157025_bb0595","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.964179","article-title":"Inflammatory mediators profile in patients hospitalized with COVID-19: a comparative study","volume":"13","author":"Tufa","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2025.157025_bb0600","series-title":"Parallels in the Pathogenesis of SARS-CoV-2 and M. Tuberculosis: a Synergistic or Antagonistic Alliance?","author":"Tapela","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0605","series-title":"The Cytokine Storm in COVID-19: An Overview of the Involvement of the Chemokine\/Chemokine-Receptor System","author":"Coperchini","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0610","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.ijid.2023.03.021","article-title":"Characterization of the immune impairment of patients with tuberculosis and COVID-19 coinfection","volume":"130","author":"Najafi-Fard","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.cyto.2025.157025_bb0615","series-title":"The COVID-19, Tuberculosis and HIV\/AIDS: m\u00e9nage \u00e0 trois","author":"Udoakang","year":"2023"},{"issue":"7","key":"10.1016\/j.cyto.2025.157025_bb0620","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.annonc.2020.03.296","article-title":"Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China","volume":"31","author":"Zhang","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cyto.2025.157025_bb0625","series-title":"COVID-19 and Cancer: Current Challenges and Perspectives","author":"Bakouny","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0630","series-title":"Cancer and COVID-19: why are cancer patients more susceptible to COVID-19?","author":"Sinha","year":"2021"},{"issue":"1","key":"10.1016\/j.cyto.2025.157025_bb0635","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/jamaoncol.2022.5357","article-title":"Interplay of immunosuppression and immunotherapy among patients with Cancer and COVID-19","volume":"9","author":"Bakouny","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.cyto.2025.157025_bb0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2020.104554","article-title":"Immunopathological similarities between COVID-19 and influenza: investigating the consequences of co-infection","volume":"152","author":"Khorramdelazad","year":"2021","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.cyto.2025.157025_bb0645","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.754241","article-title":"Phillyrin for COVID-19 and influenza co-infection: a potential therapeutic strategy targeting host based on bioinformatics analysis","volume":"12","author":"Lai","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cyto.2025.157025_bb0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2024.199371","article-title":"Interaction and antiviral treatment of coinfection between SARS-CoV-2 and influenza in vitro","volume":"345","author":"Liu","year":"2024","journal-title":"Virus Res."},{"issue":"1","key":"10.1016\/j.cyto.2025.157025_bb0655","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12879-025-10521-5","article-title":"Co-infection of SARS-CoV-2 and influenza a\/B among patients with COVID-19: a systematic review and meta-analysis","volume":"25","author":"Golpour","year":"2025","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.cyto.2025.157025_bb0660","series-title":"SARS-CoV-2 causes a different cytokine response compared to other cytokine storm-causing respiratory viruses in severely ill patients","author":"Olbei","year":"2021"},{"issue":"2","key":"10.1016\/j.cyto.2025.157025_bb0665","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J. Pathol."},{"key":"10.1016\/j.cyto.2025.157025_bb0670","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cyto.2018.01.025","article-title":"MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile","volume":"104","author":"Mahallawi","year":"2018","journal-title":"Cytokine"},{"issue":"10","key":"10.1016\/j.cyto.2025.157025_bb0675","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nm1477","article-title":"Fatal outcome of human influenza a (H5N1) is associated with high viral load and hypercytokinemia","volume":"12","author":"De Jong","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.cyto.2025.157025_bb0680","series-title":"Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","author":"Wu","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0685","doi-asserted-by":"crossref","unstructured":"D. Ellinghaus et al., \u2018The ABO blood group locus and a chromosome 3 gene cluster associate with SARS-CoV-2 respiratory failure in an Italian-Spanish genome-wide association analysis\u2019, doi: https:\/\/doi.org\/10.1101\/2020.05.31.20114991.","DOI":"10.1101\/2020.05.31.20114991"},{"key":"10.1016\/j.cyto.2025.157025_bb0690","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.719115","article-title":"Genetic screening for TLR7 variants in young and previously healthy men with severe COVID-19","volume":"12","author":"Solanich","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2025.157025_bb0695","series-title":"COVID-19 and the human innate immune system","author":"Schultze","year":"2021"},{"issue":"3","key":"10.1016\/j.cyto.2025.157025_bb0700","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0300306","article-title":"Risk factors for critical COVID-19 illness during Delta- and omicron-predominant period in Korea; using K-COV-N cohort in the national health insurance service","volume":"19","author":"Lee","year":"2024","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.cyto.2025.157025_bb0705","doi-asserted-by":"crossref","DOI":"10.1099\/jmm.0.001558","article-title":"SARS-CoV-2 seroprevalence in hospital healthcare workers in Western Switzerland at the end of the second pandemic wave","volume":"71","author":"Jacot","year":"2022","journal-title":"J. Med. Microbiol."},{"issue":"3","key":"10.1016\/j.cyto.2025.157025_bb0710","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s41591-020-01227-z","article-title":"Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics","volume":"27","author":"Muus","year":"2021","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.cyto.2025.157025_bb0715","article-title":"Malnutrition is associated with severe outcome in elderly patients hospitalised with COVID-19","volume":"14","author":"Wang","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cyto.2025.157025_bb0720","author":"Bastard"},{"key":"10.1016\/j.cyto.2025.157025_bb0725","unstructured":"X. Wei et al., Sex Differences in Severity and Mortality Among Patients With COVID-19: Evidence from Pooled Literature Analysis and Insights from Integrated Bioinformatic Analysis."},{"issue":"11","key":"10.1016\/j.cyto.2025.157025_bb0730","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.4103\/jfmpc.jfmpc_769_21","article-title":"Gender and genetic factors impacting COVID-19 severity","volume":"10","author":"Ranjan","year":"2021","journal-title":"J. Family Med. Prim. Care"},{"key":"10.1016\/j.cyto.2025.157025_bb0735","series-title":"A preliminary observation: male pattern hair loss among hospitalized COVID-19 patients in Spain \u2013 a potential clue to the role of androgens in COVID-19 severity","author":"Goren","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0740","series-title":"The interplay between inflammatory pathways and COVID-19: a critical review on pathogenesis and therapeutic options","author":"Choudhary","year":"2021"},{"key":"10.1016\/j.cyto.2025.157025_bb0745","series-title":"COVID-19 in Africa: an ovarian victory?","author":"Dufailu","year":"2021"},{"key":"10.1016\/j.cyto.2025.157025_bb0750","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01931","article-title":"Sex hormones determine immune response","volume":"9","author":"Taneja","year":"2018","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.cyto.2025.157025_bb0755","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.2337\/dc20-0576","article-title":"Obesity and COVID-19 severity in a designated Hospital in Shenzhen, China","volume":"43","author":"Cai","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cyto.2025.157025_bb0760","doi-asserted-by":"crossref","DOI":"10.1017\/S0950268820003179","article-title":"Obesity is associated with severe COVID-19 but not death: a dose\u2212response meta-analysis","volume":"149","author":"Deng","year":"2021","journal-title":"Epidemiol. Infect."},{"key":"10.1016\/j.cyto.2025.157025_bb0765","series-title":"Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19)","author":"Bourgonje","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0770","article-title":"Effects of environmental factors on severity and mortality of COVID-19","volume":"7","author":"Kifer","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"issue":"4","key":"10.1016\/j.cyto.2025.157025_bb0775","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41435-023-00249-0","article-title":"Environmental variation and genetic diversity contribute to population differences in immune responses to SARS-CoV-2 and COVID-19 risk","volume":"25","author":"Rotival","year":"2024","journal-title":"Genes Immun."},{"key":"10.1016\/j.cyto.2025.157025_bb0780","author":"Baker"},{"issue":"2","key":"10.1016\/j.cyto.2025.157025_bb0785","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2213-2600(20)30511-7","article-title":"Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"Monk","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.cyto.2025.157025_bb0790","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.706901","article-title":"Remdesivir and cyclosporine synergistically inhibit the human coronaviruses OC43 and SARS-CoV-2","volume":"12","author":"Hsu","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.cyto.2025.157025_bb0795","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.matt.2021.09.022","article-title":"Inhaled ACE2-engineered microfluidic microsphere for intratracheal neutralization of COVID-19 and calming of the cytokine storm","volume":"5","author":"Wang","year":"2022","journal-title":"Matter"},{"key":"10.1016\/j.cyto.2025.157025_bb0800","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.amsu.2020.11.027","article-title":"Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease","volume":"60","author":"Fatima","year":"2020","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.cyto.2025.157025_bb0805","author":"Ray"},{"issue":"3","key":"10.1016\/j.cyto.2025.157025_bb0810","doi-asserted-by":"crossref","first-page":"E216","DOI":"10.1093\/cid\/ciac523","article-title":"Early treatment of high-risk hospitalized coronavirus disease 2019 (COVID-19) patients with a combination of interferon Beta-1b and Remdesivir: a phase 2 open-label randomized controlled trial","volume":"76","author":"Tam","year":"2023","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.cyto.2025.157025_bb0815","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1016\/S2665-9913(20)30127-2","article-title":"Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study","volume":"2","author":"Cavalli","year":"2020","journal-title":"Lancet Rheumatol."},{"issue":"7","key":"10.1016\/j.cyto.2025.157025_bb0820","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1016\/S2665-9913(20)30164-8","article-title":"Anakinra for severe forms of COVID-19: a cohort study","volume":"2","author":"Huet","year":"2020","journal-title":"Lancet Rheumatol."},{"issue":"3","key":"10.1016\/j.cyto.2025.157025_bb0825","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jmii.2020.03.005","article-title":"TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib","volume":"53","author":"Wu","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.cyto.2025.157025_bb0830","author":"Bizzarri"},{"key":"10.1016\/j.cyto.2025.157025_bb0835","series-title":"Azithromycin through the Lens of the COVID-19 treatment","author":"Kournoutou","year":"2022"},{"key":"10.1016\/j.cyto.2025.157025_bb0840","series-title":"Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19","author":"Luo","year":"2020"},{"issue":"20","key":"10.1016\/j.cyto.2025.157025_bb0845","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cyto.2025.157025_bb0850","series-title":"Focus shifts to antibody cocktails for COVID-19 cytokine storm","author":"Harrison","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0855","series-title":"Role for anti-cytokine therapies in severe coronavirus disease 2019","author":"Buckley","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0860","series-title":"Current Strategies in Treating Cytokine Release Syndrome Triggered by Coronavirus SARS-CoV-2","author":"Wang","year":"2022"},{"key":"10.1016\/j.cyto.2025.157025_bb0865","series-title":"Controlling cytokine storm is vital in COVID-19","author":"Tang","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0870","series-title":"Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19","author":"Ma","year":"2020"},{"issue":"12","key":"10.1016\/j.cyto.2025.157025_bb0875","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1089\/scd.2020.0080","article-title":"Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19","volume":"29","author":"Sengupta","year":"2020","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.cyto.2025.157025_bb0880","series-title":"Efficacy and safety of integrated traditional Chinese and Western medicine against COVID-19: a systematic review and meta-analysis","author":"Zhuang","year":"2022"},{"issue":"15","key":"10.1016\/j.cyto.2025.157025_bb0885","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/cid\/ciaa329","article-title":"Is there an association between COVID-19 mortality and the renin-angiotensin system? A call for epidemiologic investigations","volume":"71","author":"Hanff","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cyto.2025.157025_bb0890","series-title":"The inhibitory effect of curcumin on virus-induced cytokine storm and its potential use in the associated severe pneumonia","author":"Liu","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0895","series-title":"Ruxolitinib and the mitigation of severe covid-19: A systematic review and meta-analysis","author":"Quiros","year":"2021"},{"key":"10.1016\/j.cyto.2025.157025_bb0900","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.biochi.2020.09.003","article-title":"May omega-3 fatty acid dietary supplementation help reduce severe complications in Covid-19 patients?","volume":"179","author":"Weill","year":"2020","journal-title":"Biochimie"},{"key":"10.1016\/j.cyto.2025.157025_bb0905","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.00752","article-title":"The potential beneficial effect of EPA and DHA supplementation managing cytokine storm in coronavirus disease","volume":"11","author":"Szab\u00f3","year":"2020","journal-title":"Front. Physiol."},{"key":"10.1016\/j.cyto.2025.157025_bb0910","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.579548","article-title":"Statins as adjuvant therapy for COVID-19 to calm the stormy immunothrombosis and beyond","volume":"11","author":"Vuorio","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cyto.2025.157025_bb0915","series-title":"Managing the cytokine storm in COVID-19: can melatonin play a part?","author":"Ganganna","year":"2021"},{"issue":"1","key":"10.1016\/j.cyto.2025.157025_bb0920","article-title":"Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID19","volume":"5","author":"Abd El-Aziz","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cyto.2025.157025_bb0925","series-title":"Mesenchymal stem cells in the treatment of COVID-19","author":"Guo","year":"2023"},{"key":"10.1016\/j.cyto.2025.157025_bb0930","series-title":"Mesenchymal stem cells: current clinical progress in ARDS and COVID-19","author":"Xiao","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0935","series-title":"COVID-19 and its therapeutics: special emphasis on mesenchymal stem cells based therapy","author":"Verma","year":"2021"},{"issue":"2","key":"10.1016\/j.cyto.2025.157025_bb0940","doi-asserted-by":"crossref","first-page":"216","DOI":"10.14336\/AD.2020.0228","article-title":"Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with covid-19 pneumonia","volume":"11","author":"Leng","year":"2020","journal-title":"Aging Dis."},{"key":"10.1016\/j.cyto.2025.157025_bb0945","doi-asserted-by":"crossref","DOI":"10.1007\/s15010-025-02506-y","article-title":"Efficacy of tocilizumab for hospitalized patients with COVID-19 pneumonia and high IL-6 levels: a randomized controlled trial","author":"Sellar\u00e8s-Nadal","year":"2025","journal-title":"Infection"},{"issue":"1","key":"10.1016\/j.cyto.2025.157025_bb0950","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial","volume":"181","author":"Salvarani","year":"2021","journal-title":"JAMA Intern. Med."},{"issue":"1","key":"10.1016\/j.cyto.2025.157025_bb0955","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaci.2020.05.019","article-title":"Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial","volume":"146","author":"Cao","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2025.157025_bb0960","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.chom.2020.07.005","article-title":"Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients","volume":"28","author":"Wang","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cyto.2025.157025_bb0965","series-title":"Effect of dexamethasone in hospitalized patients with COVID-19 \u2013 preliminary report","author":"Horby","year":"2020"},{"issue":"21","key":"10.1016\/j.cyto.2025.157025_bb0970","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1056\/NEJMoa2022926","article-title":"Effect of hydroxychloroquine in hospitalized patients with Covid-19","volume":"383","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2025.157025_bb0975","doi-asserted-by":"crossref","DOI":"10.1177\/09636897211024942","article-title":"The systematic effect of mesenchymal stem cell therapy in critical COVID-19 patients: a prospective double controlled trial","volume":"30","author":"Adas","year":"2021","journal-title":"Cell Transplant."},{"issue":"3","key":"10.1016\/j.cyto.2025.157025_bb0980","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1164\/rccm.202302-0297OC","article-title":"Repair of acute respiratory distress syndrome in COVID-19 by stromal cells (REALIST-COVID trial) a multicenter, randomized, controlled clinical trial","volume":"208","author":"Gorman","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cyto.2025.157025_bb0985","doi-asserted-by":"crossref","DOI":"10.3949\/ccjm.88a.ccc074","article-title":"Monoclonal antibodies for treating COVID-19","author":"Pallotta","year":"2021","journal-title":"Cleve. Clin. J. Med."},{"key":"10.1016\/j.cyto.2025.157025_bb0990","series-title":"Monoclonal antibody as a potential anti-COVID-19","author":"Jahanshahlu","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb0995","series-title":"Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19","author":"Patel","year":"2021"},{"key":"10.1016\/j.cyto.2025.157025_bb1000","unstructured":"D.-D. Wu, A. F. Kombo, Z.-G. Ren, D.-Y. Wang, and X.-Y. Ji, \u2018East African Scholars Journal of Medicine and Surgery Abbreviated Key Title: EAS J Med Surg The Possible Therapeutic Options against COVID-19\u2019, doi: 10.36349\/easjms.2021.v03i10.003."},{"key":"10.1016\/j.cyto.2025.157025_bb1005","series-title":"Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19","author":"Geng","year":"2021"},{"key":"10.1016\/j.cyto.2025.157025_bb1010","series-title":"The potential for repurposing anti-TNF as a therapy for the treatment of COVID-19","author":"Robinson","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb1015","series-title":"Dexamethasone to combat cytokine storm in COVID-19: clinical trials and preliminary evidence","author":"Sharun","year":"2020"},{"issue":"1","key":"10.1016\/j.cyto.2025.157025_bb1020","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-80654-x","article-title":"Corticosteroid treatment has no effect on hospital mortality in COVID-19 patients","volume":"11","author":"Albani","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cyto.2025.157025_bb1025","author":"Rudra Deva"},{"key":"10.1016\/j.cyto.2025.157025_bb1030","series-title":"Add-on effect of Chinese herbal medicine in the treatment of mild to moderate COVID-19: a systematic review and meta-analysis","author":"Du","year":"2021"},{"key":"10.1016\/j.cyto.2025.157025_bb1035","series-title":"Potential therapeutic effect of traditional Chinese medicine on coronavirus disease 2019: a review","author":"Qiu","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb1040","series-title":"Chloroquine and Hydroxychloroquine: Efficacy in the Treatment of the COVID-19","first-page":"217","volume":"vol. 10","author":"Ho","year":"2021"},{"key":"10.1016\/j.cyto.2025.157025_bb1045","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101663","article-title":"Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study","volume":"34","author":"Gautret","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"key":"10.1016\/j.cyto.2025.157025_bb1050","series-title":"Breakthrough: Chloroquine Phosphate Has Shown Apparent Efficacy in Treatment of COVID-19 Associated Pneumonia in Clinical Studies","author":"Gao","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb1055","doi-asserted-by":"crossref","unstructured":"M. Mah\u00e9vas et al., \u2018No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial\u2019, doi: https:\/\/doi.org\/10.1101\/2020.04.10.20060699.","DOI":"10.1101\/2020.04.10.20060699"},{"key":"10.1016\/j.cyto.2025.157025_bb1060","series-title":"Administration of intravenous immunoglobulin in the treatment of COVID-19: a review of available evidence","author":"Moradimajd","year":"2021"},{"key":"10.1016\/j.cyto.2025.157025_bb1065","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107732","article-title":"Efficacy of IVIG (intravenous immunoglobulin) for corona virus disease 2019 (COVID-19): a meta-analysis","volume":"96","author":"Xiang","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cyto.2025.157025_bb1070","series-title":"Mechanisms of potential therapeutic utilization of mesenchymal stem cells in COVID-19 treatment","author":"Fang","year":"2023"},{"key":"10.1016\/j.cyto.2025.157025_bb1075","series-title":"Immunomodulatory mechanisms of mesenchymal stem cells and their potential clinical applications","author":"Huang","year":"2022"},{"issue":"1","key":"10.1016\/j.cyto.2025.157025_bb1080","article-title":"Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial","volume":"5","author":"Meng","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.cyto.2025.157025_bb1085","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-023-03402-8","article-title":"Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial","volume":"14","author":"Zarrabi","year":"2023","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.cyto.2025.157025_bb1090","series-title":"Systematic review and meta-analysis of mesenchymal stromal\/stem cells as strategical means for the treatment of COVID-19","author":"Taufiq","year":"2023"},{"key":"10.1016\/j.cyto.2025.157025_bb1095","series-title":"Efficacy and safety of mesenchymal stem cells therapy in COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials","author":"Lu","year":"2024"},{"issue":"1","key":"10.1016\/j.cyto.2025.157025_bb1100","doi-asserted-by":"crossref","DOI":"10.1155\/ijod\/5517092","article-title":"The protective effects of MSC-derived exosomes against chemotherapy-induced parotid gland cytotoxicity","volume":"2025","author":"Bakr","year":"2025","journal-title":"Int. J. Dent."},{"key":"10.1016\/j.cyto.2025.157025_bb1105","series-title":"Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment","author":"Jayaramayya","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb1110","series-title":"Tissue repair strategies: what we have learned from COVID-19 in the application of MSCs therapy","author":"Li","year":"2022"},{"key":"10.1016\/j.cyto.2025.157025_bb1115","series-title":"Efficacy and safety of mesenchymal stem cell therapy in liver cirrhosis: a systematic review and meta-analysis","author":"Lu","year":"2023"},{"key":"10.1016\/j.cyto.2025.157025_bb1120","series-title":"Mesenchymal stem cell-based therapy and exosomes in COVID-19: current trends and prospects","author":"Abdelgawad","year":"2021"},{"issue":"3","key":"10.1016\/j.cyto.2025.157025_bb1125","doi-asserted-by":"crossref","first-page":"252","DOI":"10.15283\/ijsc20182","article-title":"Mesenchymal stem cell-derived exosomes for Covid-19 therapy, preclinical and clinical evidence","volume":"14","author":"Kiaie","year":"2021","journal-title":"Int. J. Stem Cells"},{"key":"10.1016\/j.cyto.2025.157025_bb1130","series-title":"Immunomodulatory Effects and Clinical Application of Exosomes Derived from Mesenchymal Stem Cells","author":"Yi","year":"2025"},{"issue":"1","key":"10.1016\/j.cyto.2025.157025_bb1135","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-020-02020-3","article-title":"Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID-19)","volume":"21","author":"Asgharpour","year":"2020","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.cyto.2025.157025_bb1140","series-title":"Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients?","author":"Chen","year":"2020"},{"issue":"2","key":"10.1016\/j.cyto.2025.157025_bb1145","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/1744-9987.13730","article-title":"Extracorporeal blood purification is associated with improvement in biochemical and clinical variables in the critically-ill COVID-19 patients","volume":"26","author":"Premu\u017ei\u0107","year":"2022","journal-title":"Ther. Apher. Dial."},{"key":"10.1016\/j.cyto.2025.157025_bb1150","series-title":"The type I interferon response in COVID-19: implications for treatment","author":"Lee","year":"2020"},{"key":"10.1016\/j.cyto.2025.157025_bb1155","article-title":"Interferons in COVID-19: missed opportunities to prove efficacy in clinical phase III trials?","volume":"10","author":"Brzoska","year":"2023","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.cyto.2025.157025_bb1160","series-title":"The role of type I interferon in the treatment of COVID-19","author":"Sodeifian","year":"2022"},{"key":"10.1016\/j.cyto.2025.157025_bb1165","series-title":"A Randomized Clinical Trial of the Efficacy and Safety of Interferon-1a in Treatment of Severe COVID-19","author":"Davoudi-Monfared","year":"2020"},{"issue":"9","key":"10.1016\/j.cyto.2025.157025_bb1170","doi-asserted-by":"crossref","first-page":"e692","DOI":"10.1016\/S2666-5247(23)00171-4","article-title":"Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study","volume":"4","author":"Zhu","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.cyto.2025.157025_bb1175","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155215","article-title":"Studying the correlation of inflammatory cytokines to COVID-19 disease","volume":"255","author":"Alkhattabi","year":"2024","journal-title":"Pathol. Res. Pract."},{"issue":"19","key":"10.1016\/j.cyto.2025.157025_bb1180","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1182\/blood.2019000962","article-title":"How I treat thrombotic thrombocytopenic purpura in pregnancy","volume":"136","author":"Ferrari","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2025.157025_bb1185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.832924","article-title":"Local and systemic immunity are impaired in end-stage-renal-disease patients treated with hemodialysis, peritoneal dialysis and kidney transplant recipients immunized with BNT162b2 Pfizer-BioNTech SARS-CoV-2 vaccine","volume":"13","author":"Piotrowska","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2025.157025_bb1190","series-title":"Cytokine storm in COVID-19: Immunopathogenesis and therapy","author":"Zanza","year":"2022"}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625001723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625001723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T21:45:02Z","timestamp":1758663902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466625001723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":238,"alternative-id":["S1043466625001723"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2025.157025","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delving deeper in the eye of the hurricane: Immunopathogenesis & molecular characterization of cytokine storm in COVID-19, association with disease severity & the therapeutic regimens","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2025.157025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"157025"}}